Yesterday, I lauded the best biopharma CEOs of 2018. Today, I give a side-eye glance to the worst.

To land on this ignominious list, biopharma CEOs had to screw up so badly over the past 12 months to set off my outrage alarm. Serial incompetence is also a qualifier. You’d think I would have trouble finding four nominees. You’d be wrong. The hard part for me is narrowing down the list to just four finalists. Enjoy your reading. You’ll get a chance to vote at the bottom of this post.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The only 2 CEOs in this contest should be Troy Hamilton and Gary Jacob. The other CEOs mentioned are geniuses compared to these two buffoons

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy